Company intelligence / Profile preview

Sensory Cloud

Boston, Massachusetts, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Sensory Cloud has reported positive Phase 2a results showing its investigational inhaled alkaline hypertonic divalent salt (HDS) aerosol (e.g., SC001) reduced cough frequency by up to 35% in patients with refractory chronic cough, with no meaningful adverse events reported. The HDS platform is being developed both as standalone and combination therapies for upper airway inflammatory diseases.

Therapeutic areas: Pulmonology
Modalities: DeviceAerosolized therapy
Industry: Therapeutic Medical Devices

Partnerships

Hyfe Inc.

Beyond the preview

Go deeper on Sensory Cloud.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sensory Cloud.

Explore the full profile